-
1
-
-
84855396777
-
Executive summary: Heart disease and stroke statistics-2012 update: A report from the American heart association
-
Roger VL, Go AS, Lloyd-Jones DM, et al. Executive summary: heart disease and stroke statistics-2012 update: a report from the American heart association. Circulation. 2012;125:188-197.
-
(2012)
Circulation.
, vol.125
, pp. 188-197
-
-
Roger, V.L.1
Go, A.S.2
Lloyd-Jones, D.M.3
-
2
-
-
79955624770
-
Coronary revascularization trends in the United States, 2001-2008
-
Epstein AJ, Polsky D, Yang F, et al. Coronary revascularization trends in the United States, 2001-2008. JAMA. 2011;305:1769-1776.
-
(2011)
JAMA.
, vol.305
, pp. 1769-1776
-
-
Epstein, A.J.1
Polsky, D.2
Yang, F.3
-
3
-
-
77955444881
-
Pathogenesis of myocardial ischemia-reperfusion injury and rationale for therapy
-
Turer AT, Hill JA. Pathogenesis of myocardial ischemia-reperfusion injury and rationale for therapy. Am J Cardiol. 2010;106:360-368.
-
(2010)
Am J Cardiol.
, vol.106
, pp. 360-368
-
-
Turer, A.T.1
Hill, J.A.2
-
4
-
-
0033807004
-
Reperfusion injury associated with one-fourth of deaths after coronary artery bypass grafting
-
Weman SM, Karhunen PJ, Penttila A, et al. Reperfusion injury associated with one-fourth of deaths after coronary artery bypass grafting. Ann Thorac Surg. 2000;70:807-812.
-
(2000)
Ann Thorac Surg.
, vol.70
, pp. 807-812
-
-
Weman, S.M.1
Karhunen, P.J.2
Penttila, A.3
-
6
-
-
79751489994
-
Association of myocardial enzyme elevation and survival following coronary artery bypass graft surgery
-
Domanski MJ, Mahaffey K, Hasselblad V, et al. Association of myocardial enzyme elevation and survival following coronary artery bypass graft surgery. JAMA. 2011;305:585-591.
-
(2011)
JAMA.
, vol.305
, pp. 585-591
-
-
Domanski, M.J.1
Mahaffey, K.2
Hasselblad, V.3
-
7
-
-
0036269528
-
Pharmacological possibilities for protection against myocardial reperfusion injury
-
Wang QD, Pernow J, Sjoquist PO, et al. Pharmacological possibilities for protection against myocardial reperfusion injury. Cardiovasc Res. 2002; 55:25-37.
-
(2002)
Cardiovasc Res.
, vol.55
, pp. 25-37
-
-
Wang, Q.D.1
Pernow, J.2
Sjoquist, P.O.3
-
8
-
-
0037418950
-
Sildenafil induces delayed preconditioning through inducible nitric oxide synthase-dependent pathway in mouse heart
-
Salloum F, Yin C, Xi L, et al. Sildenafil induces delayed preconditioning through inducible nitric oxide synthase-dependent pathway in mouse heart. Circ Res. 2003;92:595-597.
-
(2003)
Circ Res.
, vol.92
, pp. 595-597
-
-
Salloum, F.1
Yin, C.2
Xi, L.3
-
9
-
-
1642344354
-
Protein kinase c plays an essential role in sildenafil-induced cardioprotection in rabbits
-
Das A, Ockaili R, Salloum F, et al. Protein kinase c plays an essential role in sildenafil-induced cardioprotection in rabbits. Am J Physiol Heart Circ Physiol. 2004;286:H1455-H1460.
-
(2004)
Am J Physiol Heart Circ Physiol.
, vol.286
-
-
Das, A.1
Ockaili, R.2
Salloum, F.3
-
10
-
-
33750593772
-
Cardioprotection with sildenafil: Implications for clinical practice
-
Raja SG. Cardioprotection with sildenafil: implications for clinical practice. Curr Med Chem. 2006;13:3155-3164.
-
(2006)
Curr Med Chem.
, vol.13
, pp. 3155-3164
-
-
Raja, S.G.1
-
11
-
-
66149148931
-
Erk phosphorylation mediates sildenafilinduced myocardial protection against ischemia-reperfusion injury in mice
-
Das A, Salloum FN, Xi L, et al. Erk phosphorylation mediates sildenafilinduced myocardial protection against ischemia-reperfusion injury in mice. Am J Physiol Heart Circ Physiol. 2009;296:H1236-H1243.
-
(2009)
Am J Physiol Heart Circ Physiol.
, vol.296
-
-
Das, A.1
Salloum, F.N.2
Xi, L.3
-
12
-
-
67650065305
-
Long-acting phosphodiesterase-5 inhibitor, tadalafil, induces sustained cardioprotection against lethal ischemic injury
-
Ahmad N, Wang Y, Ali AK, et al. Long-acting phosphodiesterase-5 inhibitor, tadalafil, induces sustained cardioprotection against lethal ischemic injury. Am J Physiol Heart Circ Physiol. 2009;297:H387-H391.
-
(2009)
Am J Physiol Heart Circ Physiol.
, vol.297
-
-
Ahmad, N.1
Wang, Y.2
Ali, A.K.3
-
13
-
-
79960002376
-
Sildenafil therapy for pulmonary hypertension before and after pediatric congenital heart surgery
-
Palma G, Giordano R, Russolillo V, et al. Sildenafil therapy for pulmonary hypertension before and after pediatric congenital heart surgery. Tex Heart Inst J. 2011;38:238-242.
-
(2011)
Tex Heart Inst J.
, vol.38
, pp. 238-242
-
-
Palma, G.1
Giordano, R.2
Russolillo, V.3
-
14
-
-
77954760631
-
Postoperative use of oral sildenafil in pediatric patients with congenital heart disease
-
Uhm JY, Jhang WK, Park JJ, et al. Postoperative use of oral sildenafil in pediatric patients with congenital heart disease. Pediatr Cardiol. 2010; 31:515-520.
-
(2010)
Pediatr Cardiol.
, vol.31
, pp. 515-520
-
-
Uhm, J.Y.1
Jhang, W.K.2
Park, J.J.3
-
15
-
-
79956154889
-
Pre-operative sildenafil and pulmonary endothelial-related complications following cardiopulmonary bypass: A randomised trial in children undergoing cardiac surgery
-
Vassalos A, Peng E, Young D, et al. Pre-operative sildenafil and pulmonary endothelial-related complications following cardiopulmonary bypass: a randomised trial in children undergoing cardiac surgery. Anaesthesia. 2011;66:472-480.
-
(2011)
Anaesthesia.
, vol.66
, pp. 472-480
-
-
Vassalos, A.1
Peng, E.2
Young, D.3
|